Leslie’s, Inc. (NASDAQ:LESL – Get Free Report)’s stock price gapped down prior to trading on Tuesday after Robert W. Baird lowered their price target on the stock from $4.00 to $3.50. The stock had previously closed at $3.51, but opened at $2.78. Robert W. Baird currently has a neutral rating on the stock. Leslie’s shares last traded at $2.80, with a volume of 812,857 shares changing hands.
Several other equities research analysts also recently weighed in on LESL. Mizuho decreased their target price on Leslie’s from $6.00 to $4.00 and set a “neutral” rating for the company in a research report on Tuesday, August 6th. Telsey Advisory Group decreased their price target on Leslie’s from $4.00 to $3.75 and set a “market perform” rating for the company in a report on Tuesday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Leslie’s has an average rating of “Hold” and a consensus target price of $3.89.
Read Our Latest Stock Analysis on LESL
Institutional Inflows and Outflows
Leslie’s Stock Up 1.2 %
The firm’s 50 day simple moving average is $2.85 and its 200 day simple moving average is $3.48. The company has a market cap of $458.58 million, a price-to-earnings ratio of -20.92, a price-to-earnings-growth ratio of 2.37 and a beta of 1.19.
About Leslie’s
Leslie’s, Inc operates as a direct-to-consumer pool and spa care brand in the United States. The company markets and sells pool and spa supplies and related products and services. It also offers various pool and spa maintenance items, such as chemicals, equipment and parts, cleaning and maintenance equipment, safety, recreational, and fitness related products.
Featured Stories
- Five stocks we like better than Leslie’s
- Basic Materials Stocks Investing
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- CD Calculator: Certificate of Deposit Calculator
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- The Most Important Warren Buffett Stock for Investors: His Own
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Leslie's Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leslie's and related companies with MarketBeat.com's FREE daily email newsletter.